Research Article
Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study
Table 1
Comparison of selected patient characteristics between the groups with rheumatoid arthritis with osteoporosis vs. without osteoporosis.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DAS28: Disease Activity Score for 28 joints; HAQ-DI: Health Assessment Questionnaire Disability Index; BMD: bone mineral density; ESR: erythrocyte sedimentation rate; ACPAs: antibodies against cyclic-citrullinated peptides/proteins included anti-CCP2 or anti-MCV; cs-DMARD: conventional synthetic-disease-modifying antirheumatic drugs; sRANKL: Soluble Receptor Activator for Nuclear Factor kappa B Ligand; OPG: osteoprotegerin; DKK-1: Dickkopf-1; SOST: sclerostin; OC: osteocalcin; CTSK: cathepsin k. Qualitative variables were expressed in frequencies (%) and quantitative variables in (SD). Statistical tests: Chi-square test (or Fisher exact test if applicable) for comparisons between proportions. Independent sample Student -tests were conducted for comparisons between means, and values were obtained comparing RA patients with osteoporosis vs. RA patients without osteoporosis. The group of patients without osteoporosis included patients with osteopenia or with normal BMD (). |